April 12, 2022
Entry of the SARS-CoV-2 coronavirus, which causes COVID-19, requires a host serine protease called TMPRSS2. Camostat mesylate, an orally available serine protease inhibitor, inhibits TMPRSS2, supporting clinical trials to investigate its use in COVID-19.
"The use of innovative modeling by Harrington gave us new insights into how to use Camostat clinically."
- Joseph Vinetz, MD
Infectious Disease, Virology
2020 Harrington Award for Coronavirus